期刊
LANCET ONCOLOGY
卷 22, 期 6, 页码 E270-E280出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/S1470-2045(20)30725-7
关键词
-
类别
资金
- Basilea Pharmaceuticals
- Cidara Therapeutics
- F2G
- Gilead Sciences
- Merck Sharp and Dohme
- Takeda
The ECIL-8 Paediatric Group reviewed literature and formulated recommendations for antibiotic use in paediatric cancer patients and those undergoing haematopoietic cell transplantation, focusing on factors such as clinical stability and previous infection or colonization by resistant bacteria.
Paediatric patients with cancer and those undergoing haematopoietic cell transplantation are at high risk of bacterial infections. The 8th European Conference on Infections in Leukaemia (ECIL-8) convened a Paediatric Group to review the literature and to formulate recommendations for the use of antibiotics according to the European Society of Clinical Microbiology and Infectious Diseases grading system. The evaluation of antibacterial prophylaxis included mortality, bloodstream infection, febrile neutropenia, emergence of resistance, and adverse effects as endpoints. Initial antibacterial therapy and antibiotic de-escalation or discontinuation focused on patients with a clinically stable condition and without previous infection or colonisation by resistant bacteria, and on patients with a clinically unstable condition or with previous infection or colonisation by resistant bacteria. The final considerations and recommendations of the ECIL-8 Paediatric Group on antibacterial prophylaxis, initial therapy, and de-escalation strategies are summarised in this Policy Review.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据